Efficacy and Safety of Upadacitinib vs Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial.
Sign Up to like & getrecommendations! Published in 2021 at "JAMA dermatology"
DOI: 10.1001/jamadermatol.2021.3023
Abstract: Importance Atopic dermatitis (AD) is a chronic, recurrent, inflammatory skin disease with an unmet need for treatments that provide rapid and high levels of skin clearance and itch improvement. Objective To assess the safety and… read more here.
Keywords: week; safety; efficacy; upadacitinib dupilumab ... See more keywords
Pharmacokinetics of Subcutaneous Dupilumab Injection With an Autoinjector Device or Prefilled Syringe
Sign Up to like & getrecommendations! Published in 2022 at "Clinical Pharmacology in Drug Development"
DOI: 10.1002/cpdd.1073
Abstract: Dupilumab, a human monoclonal antibody against interleukin‐4 receptor alpha, has demonstrated efficacy and an acceptable safety profile in adult and pediatric patients with moderate‐to‐severe atopic dermatitis (AD) and other type 2 inflammatory diseases. Dupilumab is… read more here.
Keywords: prefilled syringe; autoinjector device; dupilumab; injection ... See more keywords
Pharmacokinetics and Concentration-Response of Dupilumab in Patients with Seasonal Allergic Rhinitis.
Sign Up to like & getrecommendations! Published in 2021 at "Journal of clinical pharmacology"
DOI: 10.1002/jcph.2004
Abstract: Patients with moderate to severe allergic rhinitis may benefit from subcutaneous immunotherapy (SCIT), despite the risk of systemic allergic reaction. Dupilumab is a fully human monoclonal antibody that blocks the shared receptor component for interleukin… read more here.
Keywords: dupilumab; concentration response; allergic rhinitis; seasonal allergic ... See more keywords
Dupilumab in children with moderate‐to‐severe asthma: A cost utility analysis
Sign Up to like & getrecommendations! Published in 2022 at "Pediatric Pulmonology"
DOI: 10.1002/ppul.26033
Abstract: Dupilumab is an effective and safe medicine for the management of severe asthma. Due to its high cost, concerns are generated regarding its cost‐effectiveness. This study aimed to estimate the cost‐utility of dupilumab plus standard… read more here.
Keywords: cost; dupilumab; severe asthma; cost utility ... See more keywords
Liberty Asthma QUEST: Phase 3 Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate Dupilumab Efficacy/Safety in Patients with Uncontrolled, Moderate-to-Severe Asthma
Sign Up to like & getrecommendations! Published in 2018 at "Advances in Therapy"
DOI: 10.1007/s12325-018-0702-4
Abstract: IntroductionDupilumab, a fully human anti-IL-4Rα monoclonal antibody, inhibits signaling of both interleukin (IL)-4 and IL-13, which are key drivers of type 2-mediated inflammation. Dupilumab is approved in the EU, USA, and other countries for the… read more here.
Keywords: phase; severe asthma; efficacy; asthma ... See more keywords
Economic Evaluation of Dupilumab for the Treatment of Moderate-to-Severe Atopic Dermatitis in Adults
Sign Up to like & getrecommendations! Published in 2017 at "Dermatology and Therapy"
DOI: 10.1007/s13555-017-0201-6
Abstract: IntroductionDupilumab significantly improves signs and symptoms of atopic dermatitis (AD), including pruritus, symptoms of anxiety and depression, and health-related quality of life versus placebo in adults with moderate-to-severe AD. Since the cost-effectiveness of dupilumab has… read more here.
Keywords: dupilumab; treatment moderate; cost; moderate severe ... See more keywords
Real-World Experience and Laboratory Monitoring of Dupilumab in Patients with Moderate to Severe Atopic Dermatitis in a Tertiary Centre
Sign Up to like & getrecommendations! Published in 2020 at "Dermatology and Therapy"
DOI: 10.1007/s13555-020-00469-6
Abstract: Introduction Dupilumab is a biologic therapy approved for treatment of moderate to severe atopic dermatitis (AD). Our objective was to assess the real-world effectiveness, safety and laboratory monitoring practices for dupilumab in a tertiary centre.… read more here.
Keywords: real world; dermatology; monitoring; laboratory ... See more keywords
Continued Treatment with Dupilumab is Associated with Improved Efficacy in Adults with Moderate-to-Severe Atopic Dermatitis Not Achieving Optimal Responses with Short-Term Treatment
Sign Up to like & getrecommendations! Published in 2021 at "Dermatology and Therapy"
DOI: 10.1007/s13555-021-00643-4
Abstract: Introduction Previous drug survival studies of dupilumab in atopic dermatitis (AD) show that many patients continue treatment through 1 year, suggesting that patients experience clinically relevant benefits with long-term treatment. Methods This post hoc analysis included… read more here.
Keywords: term treatment; treatment; dupilumab; term ... See more keywords
Résultats des données biologiques de tolérance pour le dupilumab chez des adolescents atteints de dermatite atopique modérée à sévère insuffisamment contrôlée ou non éligible à un traitement topique
Sign Up to like & getrecommendations! Published in 2019 at "Annales De Dermatologie Et De Venereologie"
DOI: 10.1016/j.annder.2019.09.587
Abstract: Introduction Le dupilumab, un anticorps monoclonal entierement humain inhibant les interleukines IL-4 et IL-13, est approuve dans plusieurs pays pour le traitement des patients adultes atteints de dermatite atopique (DA) moderee a severe insuffisamment controlee. L’efficacite… read more here.
Keywords: des adolescents; chez des; dupilumab; atteints dermatite ... See more keywords
Analyse des patients non-répondeurs au dupilumab traités pour une dermatite atopique en vie réelle
Sign Up to like & getrecommendations! Published in 2020 at "Annales De Dermatologie Et De Venereologie"
DOI: 10.1016/j.annder.2020.09.095
Abstract: Introduction Le dupilumab a montre son efficacite et securite dans la dermatite atopique (DA). L’objectif de l’etude etait d’etudier les caracteristiques des patients n’ayant pas ou peu de reponse au dupilumab en vie reelle. Materiel… read more here.
Keywords: scorad; amelioration; vie; dupilumab ... See more keywords
Dupilumab shows long-term safety and efficacy in moderate-to-severe atopic dermatitis patients enrolled in a phase 3 open-label extension study.
Sign Up to like & getrecommendations! Published in 2019 at "Journal of the American Academy of Dermatology"
DOI: 10.1016/j.jaad.2019.07.074
Abstract: BACKGROUND Significant unmet need exists for long-term treatment of moderate-to-severe atopic dermatitis (AD). OBJECTIVE To assess long-term safety and efficacy of dupilumab in AD patients. METHODS This ongoing, multicenter, open-label extension (OLE) study (NCT01949311) evaluated… read more here.
Keywords: long term; safety; efficacy; dupilumab ... See more keywords